Featured Articles

  • RNA rocks on

    Tuesday, September 01, 2026
    As the next generation of RNA therapeutics takes the CGT stage, the technology is moving beyond its COVID-era breakout role. It could enable new approaches to in vivo CAR-T, address diseases beyond the reach of conventional gene replacement... read more

  • Global by default

    Wednesday, August 26, 2026
    For many CGT companies, the U.S. has long been the default starting point for new ventures. In recent years, that model appears to be weakening, as more companies look beyond the U.S. earlier in their development. read more

  • RNA's comeback tour

    Wednesday, August 19, 2026
    RNA’s reputation may have been forged by a pandemic, but its future will likely be determined by something far less dramatic: the steady accumulation of clinical data, regulatory milestones and, ultimately, patient benefit read more

  • CGT’s unfinished business

    Monday, August 17, 2026
    Developers who build regulatory strategy into their manufacturing planning from the outset and design to the highest applicable cross-regional standard, will be better positioned to navigate complexity and deliver therapies to patients. read more

  • CDMO roundtable: Who owns risk? How are you improving knowledge transfer?

    Monday, August 17, 2026
    We invited cell and gene therapy CDMOs to discuss the most common pressure points in sponsor relationships. read more

  • What cell and gene therapy CDMOs want sponsors to know

    Tuesday, August 11, 2026
    In this roundtable series, CDMOs describe what works — and what doesn’t — in sponsor relationships read more

  • CDMO roundtable: At what stage should sponsors begin engaging CDMOs?

    Tuesday, August 11, 2026
    We invited cell and gene therapy CDMOs to discuss the most common pressure points in sponsor relationships. read more

  • Logic-gated CAR-T

    Wednesday, July 08, 2026
    As logic-gated CAR-Ts advance into human studies, the field is moving toward multi-layered platforms that integrate Boolean logic, microenvironmental sensing, enhanced trafficking, and dynamic control of T-cell behavior, with the goal of ... read more

  • Cell therapy’s real cost problem starts in the culture flask

    Monday, June 29, 2026
    Some of the most actionable levers may sit earlier in the process than the industry has been looking. read more

  • Avoiding CMC pitfalls

    Tuesday, June 23, 2026
    A clear CMC roadmap is critical as global regulators expect to see not only a snapshot of current controls but a clear path showing how a process will mature and scale throughout development and commercialization. read more

  • Refining the molecular blueprint of in vivo CAR-T

    Thursday, June 18, 2026
    Laboratory management software can’t build a perfectly optimized construct for an in vivo CAR-T cell therapy, but it can make the lives of the scientists doing so considerably easier. read more

  • Placenta as the missing link

    Monday, June 15, 2026
    When you combine an ethical, plentiful human tissue source with disciplined manufacturing and true codevelopment partnerships, you get a realistic way to scale human-derived biomaterials. read more
Page